And then there were 8: Fresenius nabs the latest Humira biosimilar approval

Anticipation is building as the US prepares to see an onslaught of biosimilars competing with AbbVie’s megablockbuster Humira in the coming months.

Fresenius Kabi said this morning that the FDA approved its citrate-free biosimilar to Humira (adalimumab), known as Idacio. This is the eighth FDA approval for an adalimumab biosimilar...

Click to view original post